Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Terns Pharmaceuticals, Inc. Director's Dealing 2023

Jun 2, 2023

32559_dirs_2023-06-02_4ffaf82a-dba1-4324-a664-06ca297fe01d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2023-05-31

Reporting Person: Yoon Seokho Bryan (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-31 Common Stock P 9997.00 $1.41 Acquired 17656.00 Direct

Footnotes

F1: Includes the purchase of 9,997 shares under the Terns Employee Stock Purchase Plan on May 31, 2023.